RFL (Rafael Holdings) FFO


RFL Rafael Holdings Inc RFL
48 GF Score
Price $2.70
GF Value $1.35
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Rafael Holdings FFO?

FFO (Funds from operations) only applies to REITs.

RFL
48GF Score
Rafael Holdings Inc RFL
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rafael Holdings (RFL) Overvalued in 2026?

Based on GuruFocus' analysis, Rafael Holdings stock appears to be overvalued. The current stock price of $2.70 is trading 100% above its estimated GF Value™ of $1.35. GuruFocus considers Rafael Holdings to be Significantly Overvalued.

Key valuation signals for RFL:

  • FFO:
  • GF Value™: $1.35 vs. price of $2.70 (100% above fair value)
  • GF Score™: 48/100 with 8 warning signs

No single metric tells the full story. See the RFL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rafael Holdings Business Description

Address 520 Broad Street, Newark, NJ, USA, 07102
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
48GF Score

Get the complete analysis for RFL

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.70
Price
$1.35
GF Value